Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + erlotinib + paclitaxel
- Development stage
- Unknown
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination regimen of three drugs used in oncology. Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, leading to apoptosis. Paclitaxel is a taxane chemotherapy that stabilizes microtubules, preventing cell division and causing cancer cell death[5][6][7]. Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which blocks EGFR signaling pathways involved in cancer cell proliferation and survival[1][2]. The combination has been studied for the treatment of advanced non-small cell lung cancer (NSCLC) and other malignancies. In clinical trials, this regimen did not show a significant survival advantage over carboplatin plus paclitaxel alone in unselected NSCLC populations but may benefit certain subgroups such as never smokers or those with EGFR mutations[1][2].
- Other names
- carboplatin/erlotinib/paclitaxelerlotinib plus carboplatin and paclitaxel
02
Targets
Beyond the preview
Go deeper on carboplatin + erlotinib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + erlotinib + paclitaxel.